Components of SurA required for outer membrane biogenesis in uropathogenic Escherichia coli

Kristin M. Watts
*Washington University School of Medicine in St. Louis*

David A. Hunstad
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Part of the [Medicine and Health Sciences Commons](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**
Watts, Kristin M. and Hunstad, David A., "Components of SurA required for outer membrane biogenesis in uropathogenic Escherichia coli." PLoS One. 3,10. e3359. (2008).
[https://digitalcommons.wustl.edu/open_access_pubs/801](https://digitalcommons.wustl.edu/open_access_pubs/801)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Components of SurA Required for Outer Membrane Biogenesis in Uropathogenic Escherichia coli

Kristin M. Watts1, David A. Hunstad1,2*

1 Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract

Background: SurA is a periplasmic peptidyl-prolyl isomerase (PPIase) and chaperone of Escherichia coli and other Gram-negative bacteria. In contrast to other PPIases, SurA appears to have a distinct role in chaperoning newly synthesized porins destined for insertion into the outer membrane. Previous studies have indicated that the chaperone activity of SurA rests in its “core module” (the N- plus C-terminal domains), based on in vivo envelope phenotypes and in vitro binding and protection of non-native substrates.

Methodology/Principal Findings: In this study, we determined the components of SurA required for chaperone activity using in vivo phenotypes relevant to disease causation by uropathogenic E. coli (UPEC), namely membrane resistance to permeation by antimicrobials and maturation of the type 1 pilus usher FimD. FimD is a SurA-dependent, integral outer membrane protein through which heteropolymeric type 1 pili, which confer bladder epithelial binding and invasion capacity upon uropathogenic E. coli, are assembled and extruded. Consistent with prior results, the in vivo chaperone activity of SurA in UPEC rested primarily in the core module. However, the PPIase domains I and II were not expendable for wild-type resistance to novobiocin in broth culture. Steady-state levels of FimD were substantially restored in the UPEC surA mutant complemented with the SurA N- plus C-terminal domains. The addition of PPIase domain I augmented FimD maturation into the outer membrane, consistent with a model in which domain I enhances stability of and/or substrate binding by the core module.

Conclusions/Significance: Our results confirm the core module of E. coli SurA as a potential target for novel anti-infective development.

Introduction

Integrity of the outer membrane (OM) of Gram-negative bacteria relies on the coordinated expression, maturation, and insertion of lipopolysaccharide and a number of integral membrane proteins. A major subset of OM proteins (OMPs), existing in monomeric or multimeric forms, adopt pore structures upon their insertion into the membrane. Recent studies have informed a model for the process by which these porins traverse the periplasm and reach their destination in the OM. Nascent polypeptides destined for OM insertion enter the periplasm via the Sec translocon as the canonical signal sequence is cleaved. Hydrophobic portions of the primary sequence, which are common to integral OM proteins, might be expected to require protection by chaperones during transit through the periplasm. The protected polypeptides are delivered to an OM protein assembly complex anchored by BamA (also known as YaeT) [1–3], which coordinates the process of insertion through incompletely understood mechanisms.

Multiple lines of evidence implicate the periplasmic peptidyl-prolyl isomerase (PPIase) SurA in the chaperoning of β-barrel porins through the periplasm. At least three families of PPIases are encoded by Escherichia coli K-12; representative periplasmic proteins are the cyclophilin PpiA [4], the FK binding protein-like isomerase FkpA [5], and two parvulin domain-containing isomerases, SurA and PpiD [6–8]. These proteins feature in common one or more PPIase domains that catalyze the in vitro isomerization of proline bonds [9]. Though FkpA also exhibits chaperone activity [10,11], SurA is uniquely positioned as a facilitator of periplasmic transit of nascent outer membrane porins. The relative lack of two major OMPs, OmpA [6] and LamB [6,12], in surA mutants of E. coli K-12 was reported by two groups in 1996. More recently, we demonstrated that the pilus usher proteins FimD and PapC were SurA-dependent OMPs [13]. Mutation in surA results in accumulation of unfolded intermediates in the periplasm [12] and activation of the σ54 stress-response system [12,14], which includes transcription of the periplasmic chaperone/ protease degP [6]. More direct evidence of the involvement of SurA in OMP trafficking through the periplasm has been provided by Silhavy and colleagues. Mutations in surA were shown to be synthetically lethal with those in degP or in skp, which encodes a distinct and structurally unrelated periplasmic chaperone [15]. Subsequent studies in which SurA was depleted in a graded fashion showed that SurA was the...
primary chaperone responsible for OMP transit, while Skp and DegP likely can compensate to an extent when OMPs fall off the SurA pathway. Further, SurA was shown to interact directly with BnaA in vivo [16].

The crystal structure of SurA from E. coli K-12, identical in primary sequence to that of other E. coli strains (including UPEC) and highly similar to those expressed by Salmonella, Shigella, and Yersinia [17,18], was solved in 2002 [19]. The protein includes four distinct structural domains: an N-terminal domain with no obvious homology to other protein families, two parvulin-like PPIase domains (herein denoted I and II), and a short C-terminal domain. In the three-dimensional structure, the N and C-terminal domains together form a “core module” that is completed by a strand from PPlase domain I, while domain II extends away from this core module [19]. In vitro, the chaperone preferentially binds peptide sequences containing two aromatic residues separated by another amino acid (Ar-X-Ar), a motif that is over-represented in integral OM proteins of E. coli compared to proteins in other cellular compartments [20–22]. Finally, other studies have suggested that the chaperone activity of SurA localizes not to its two parvulin-like PPlase domains, but to its N-terminal substrate-binding domain. These studies relied on its interaction with non-native substrates, namely protection of citrate synthase from aggregation and binding to somatostatin [14,23]. In this study, we aimed to investigate the components of SurA necessary for chaperone action in a pathogenic strain of E. coli and using chromosomally expressed, native SurA-dependent proteins. We interrogated SurA function using in vivo phenotypes relevant to E. coli uropathogenesis, namely resistance to membrane-impermeable antimicrobials and surface expression of the type 1 pilus usher FimD.

Materials and Methods

Bacterial strains and media

E. coli was grown in Luria-Bertani (LB) medium or Mueller-Hinton medium as indicated (Difco, Becton-Dickinson, Sparks, MD). UPEC strain UTI89 was recovered from the urine of a patient with cystitis [24]; C600 is a laboratory E. coli K-12 strain used for protein production. The UTI89 surA mutant was created by insertional disruption as described [25]. A panel of SurA domain constructs in the expression vector pQE30 was kindly provided by Dr. Susanne Behrens [14]. The coding region of each construct was amplified by high-fidelity PCR (Stratagene, La Jolla, CA) incorporating an XbaI site into the reverse primer. PCR products were digested with EcoRI and XbaI, and each resulting fragment was then ligated into the expression vector pTRC99 (GE Healthcare/Pharmacia, Piscataway, NJ). Empty vector (denoted pEV) and vector encoding full-length, native SurA (called pDH23) were included as controls where indicated. Expression was induced by addition of isopropyl β-D-thiogalactopyranoside (IPTG; Sigma, St. Louis, MO) at the indicated concentrations.

Fractionation and Western immunoblotting

For periplasm preparation, cultures of the indicated strains grown in LB broth were harvested at mid-logarithmic phase, after IPTG induction during the last 40 min of growth. Cell pellets were resuspended in 20 mM Tris (pH 8.0) with 20% (w/v) sucrose; EDTA was added to 5 mM and lysozyme to 80 μg/mL, and the mixture was incubated on ice 20 min. MgCl₂ was added to 25 mM and cell debris was pelleted by centrifugation. Supernatants (periplasms) were stored at 20°C; cell debris was pelleted by centrifugation. Supernatants (representing inner membranes) were decanted and the pellets (outer membranes) were resuspended in Tris buffer. For detection of SurA variants, equal amounts of identically prepared periplasmic fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (PVDF; Millipore, Billerica, MA). Full-length SurA with a 6-histidine tag was expressed in E. coli strain C600 and purified by metal-affinity chromatography. Antibodies directed against full-length SurA were raised in mice using standard Freund’s adjuvant-based immunization and serum collection techniques, according to a protocol approved by the institutional Animal Studies Committee. Bound anti-SurA antibodies were recognized with alkaline phosphatase-conjugated anti-mouse IgG and visualized using BCIP/NBT substrate (both from Sigma). For FimD immunoblotting, outer membrane fractions were subjected to SDS-PAGE, transferred to PVDF membranes, and overlaid with mouse antiserum to FimD (MedImmune, Gaithersburg, MD). Bound anti-FimD antibodies were detected with peroxidase-conjugated anti-mouse IgG (Sigma) and visualized with CDP-Star substrate (Tropix Inc., Bedford, MA) and ECL Hyperfilm (GE Healthcare/Amersham, Pittsburgh, PA). For presentation, blots were scanned using an Epson 4470 scanner and band intensities quantified with ImageJ software (National Institutes of Health, Bethesda, MD). Data presented are representative of multiple independent experiments.

Novobiocin growth assays

For disk diffusion assays, overnight cultures of the indicated strains in Mueller-Hinton broth (containing selective antibiotic) were subcultured, grown to equivalent optical densities, and swabbed in a lawn on freshly prepared Mueller-Hinton agar plates containing 0.01 mM IPTG. Filter paper disks containing 30 μg novobiocin (Becton-Dickinson) were placed on the agar, and the diameter of the zone of clearance was recorded after a second overnight incubation at 37°C. For bacterial growth curves, overnight cultures of the indicated strains were subcultured 1:200 into fresh LB broth (with antibiotics and IPTG) in wells of a 24-well plate, then shaken at 37°C in a Synergy 2 multimode microplate reader (Bio-Tek, Winooski, VT) with absorbance readings at 600 nm recorded every 30 min.

In vitro hemagglutination (HA), binding and invasion

Type 1 pilus-dependent hemagglutination of guinea pig erythrocytes (Colorado Serum Co., Denver, CO) was assayed in 96-well V-bottom plates as described previously [19]. For binding and invasion experiments, cultured 5637 human bladder epithelial cells (ATCC HTB-9) were obtained from the American Type Culture Collection (Manassas, VA) and grown in RPMI 1640 medium ( Gibco/Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum (Sigma) at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Two days prior to assay, cells were detached with trypsin (0.05%) plus EDTA (0.02%), centrifuged, resuspended in fresh medium, and allocated to wells of sterile 24-well tissue culture plates. On the day of assay, confluent monolayers were washed once with sterile PBS, and fresh medium was applied prior to infection with 10⁷ CFU/mL of the indicated strains. Quantitation of cell-associated bacteria and
invaded bacteria (via gentamicin protection) was performed as previously described [26].

Statistical analysis
Two-tailed Student’s T-tests were used for comparison of numerical data. For binding and invasion assays, relative binding and invasion by UPEC expressing SurA variants was reported as proportional to wild-type UPEC in each experiment, and the aggregate data were presented and statistically compared. A p value of less than 0.05 was considered statistically significant.

Results and Discussion
Expression of SurA domain variants in UPEC
The set of domain constructs used in this study is shown in Figure 1A. For our studies, we excluded constructs that encoded the N-terminal domain but lacked the C-terminal domain, because the resulting polypeptides were previously found to be unstable ([14] and S. Behrens, personal communication). The remaining domain constructs were migrated to a different expression system and host strain than that earlier described [14]; therefore, we first evaluated expression of the domain variants in a uropathogenic strain of E. coli. Periplasms were prepared from UTI89 surA::kan complemented with full-length surA (on plasmid pDH23) or each of these domain constructs (induced with 0.01 mM IPTG). The periplasms were subjected to SDS-PAGE and immunoblotting using mouse antiserum raised against full-length SurA. Constructs containing the N- and C-terminal domains, with and without the PP1ase domains (i.e., N+C, N+I+C, N+II+C, and full-length SurA) were all detectable at predicted sizes by Western blotting with mouse polyclonal antiserum raised against full-length SurA (Figure 1B). The combination of domains I+II was also detected readily; of these individual domains, domain II was more prominent than domain I on multiple blots. These results are generally consistent with those found in the constructs’ original expression system in E. coli K-12 [14], with the exception that domain I appears less stable than domain II when expressed alone in the uropathogen. Steady-state periplasmic levels of the SurA variants with induction at higher IPTG concentrations (up to 0.1 mM) were not significantly different (data not shown).

Membrane permeability and antibiotic resistance
To determine general effects on the membrane of UPEC during complementation of the surA mutant with the SurA domain constructs, we assessed growth in the presence of novobiocin, a hydrophobic aminocoumarin antibiotic and inhibitor of DNA gyrase [27] that normally does not penetrate the Gram-negative cell envelope. We have previously demonstrated that lack of SurA imparts susceptibility to novobiocin in E. coli K-12 [13]. As measured by disk diffusion with 11-mm, 30-μg novobiocin filter paper disks, growth inhibition of the UTI89 surA mutant was significantly greater than that of wild-type UTI89 (Figure 2A). Complementation of the mutant with constructs containing the N- plus C-terminal domains of SurA restored wild-type resistance; inclusion of domain I or II did not significantly alter this phenotype. In contrast, domains I or II alone or in combination, though stably expressed, did not restore novobiocin resistance (p > 0.001 versus wild type). We next proceeded to examine novobiocin susceptibility in an alternative way, namely the growth of the same strains in LB broth culture containing 10 μg/mL of novobiocin. Under these conditions, the N and C-terminal domains together substantially restored novobiocin resistance to the surA mutant (Figure 2B), and addition of domain I (but not domain II) augmented growth (p < 0.05). The broth culture experiments were therefore more sensitive in detecting a role for domain I; such a role might relate either to stability of the SurA “core module” (as suggested by Figure 1B) or perhaps to aspects of SurA function, such as substrate binding.

Type 1 pilus-dependent phenotypes of UPEC
The capacity of UPEC to bind and invade the bladder epithelium is conferred by type 1 pilus and, more specifically, by the mannose-sensitive type 1 tip adhesin FimH [26]. Our recent
work demonstrated that inactivation of \textit{surA} in \textit{E. coli} K-12 or in UTI89 resulted in significantly decreased piliation, corresponding with a decrement in steady-state levels of the type 1 pilus usher FimD in the OM [13,28]. We applied similar analyses to the UTI89 \textit{surA} mutant complemented with \textit{SurA} domain variants. First we assayed the agglutination of guinea pig erythrocytes, an \textit{in vitro} phenotype dependent on FimH, by UTI89 expressing the \textit{SurA} variants. Consistent with our previous results, loss of \textit{SurA} led to a significant reduction in hemagglutination (HA) titer (Figure 3), and the residual HA was inhibited by the addition of 2% methyl-\textit{a}-D-mannopyranoside (data not shown). Complementation with full-length \textit{SurA} or with the N- plus C-terminal domains substantially restored the HA titer. Inclusion of domain I or II did not provide an additive effect on the HA titer, and domains I and/or II alone provided no complementation. For N+C, N+I+C, and N+II+C, increases in the concentration of inducer (to 0.1 mM IPTG) caused piliation levels and HA titers to decrease (data not shown), suggesting that accumulation of imperfect variants in the periplasm or occupation of other chaperone or periplasmic stress-response systems had a detrimental effect on pilus assembly and presentation.

To more specifically investigate the relevant type 1-dependent functions of the \textit{SurA} variant strains, we next assayed the binding and invasion of cultured human bladder epithelial cells by UPEC expressing the \textit{SurA} variants. Confluent monolayers of 5637 human bladder epithelial cells were infected with each strain; binding was evaluated after washing and homogenization of the monolayers, and invasion was assessed by gentamicin protection.

Figure 2. Restoration of novobiocin resistance in UTI89 by \textit{SurA} variants. (A) Susceptibility to novobiocin is reported as the diameter of the zone of inhibition around 11-mm novobiocin disks after overnight incubation on Mueller-Hinton agar. Thus, wild-type UTI89 (leftmost bar) grows up to the disk edge (disk diameter indicated by gray line), and the \textit{surA} mutant is susceptible to novobiocin under these conditions. Resistance is complemented by full-length \textit{SurA} or the N+C domains. Domains I and/or II alone do not restore novobiocin resistance (*p<0.001 vs. UTI89); either domain I or II, when included with the N+C domains, bolsters resistance by a nonsignificant amount. Results represent the average of three separate experiments. (B) Growth of the indicated strains in LB broth containing 10 mg/mL novobiocin. The \textit{surA} mutant is nonviable (black circles), and complementation with full-length \textit{SurA} (on pDH23; gray squares) restores growth equivalent to wild-type UTI89 (black diamonds). Under these conditions, the N+C variant incompletely rescues novobiocin resistance (black triangles), and a small but significant contribution of domain I to novobiocin resistance is revealed (gray triangles; p<0.05 versus N+C from 2 to 8 h). Absent growth of the \textit{surA} mutant complemented with empty vector, pSurAI, pSurAII, or pSurAII was indistinguishable from the \textit{surA} mutant itself; these curves were omitted from the graph for clarity. doi:10.1371/journal.pone.0003359.g002
Consistent with our prior results [28], there was a sharp decrement in epithelial binding by the surA mutant when compared with wild-type UTI89, and this defect was complemented by provision of full-length surA in trans (Figure 4). Domain constructs encoding both the N- and C-terminal domains of SurA substantially but incompletely restored both binding and invasion (p < 0.04 for binding and invasion versus the surA mutant, either alone or with empty vector; p < 0.0001 for binding and p < 0.002 for invasion versus wild type). The addition of either domain I or II to the N- plus C-terminal domains had no significant impact on binding but conferred significant increases in invasion (p < 0.01 for each comparison versus N+C). Binding and invasion by UTI89 expressing SurA variants including only domains I and/or II (without the core module) were indistinguishable from the surA mutant.

Steady-state production of FimD

Our previous data suggested that the type 1 pilus usher FimD is a SurA-dependent OM protein, and that failed maturation of this usher underlies defective piliation in surA mutants. Therefore, we examined the steady-state levels of FimD in UTI89 and the surA mutant expressing the SurA domain variants by Western blotting of outer membranes harvested from these strains. Consistent with prior results, disruption of surA led to a notable decrement in the presentation of FimD, and this was restored by complementation with full-length SurA (Figure 5). Mirroring the invasion data, domains N+C substantially restored FimD presence in the OM, and addition of domain I slightly augmented FimD levels. The PPIase domains alone contributed no support of FimD maturation in the OM. This experiment provides further evidence that the defect in type 1 piliation of surA mutants is due to failed maturation of FimD. In addition, our combined studies of the relationship between SurA and the type 1 pilus assembly system indicate that pilus production in UPEC relies primarily on activity of the core module of SurA and suggest a contribution from the PPIase domain(s), particularly domain I. Finally, we conclude that type 1 pilus and pilus-dependent functions in UPEC are proportional to the amount of usher present in the OM, suggesting that usher maturation might represent a means by which the bacterial cell can regulate the presentation of pili under different conditions.

Figure 3. Hemagglutination (HA) by SurA domain-complemented UTI89. Uniform suspensions of the indicated strains were mixed with a series of two-fold dilutions of guinea pig erythrocytes, and the overnight HA titer is shown. HA is substantially complemented by full-length SurA or any of the N+C-containing variants, while domains I and II (alone or in combination) fail to complement the HA defect of the surA mutant (*p < 0.01 versus WT). Results are representative of three separate experiments.

doi:10.1371/journal.pone.0003359.g003

Figure 4. Binding and invasion of cultured bladder epithelial cells by SurA domain-complemented UTI89. Relative binding and invasion capacities are shown as a proportion of wild-type UTI89 binding and invasion; results for each strain represent the aggregate of at least three independent experiments. Binding and invasion are significantly reduced in the surA mutant. The three variants containing the N+C domains substantially restored binding and invasion (p < 0.04 versus surA mutant), but below wild-type levels (p < 0.0001 versus WT for binding; p < 0.002 for invasion). Addition of domain I or II to N+C was associated with a significant increase in invasion capacity (p < 0.01). The three SurA variants containing only domains I and/or II failed to restore these type 1 pilus-dependent functions (p < 0.0001 versus WT for both binding and invasion).

doi:10.1371/journal.pone.0003359.g004

Figure 5. Usher levels in the OM. Steady-state levels of FimD in total membrane extracts from the indicated strains were determined by SDS-PAGE followed by Western immunoblotting (upper panel) using a mouse antiserum to FimD. Quantitation of band intensity is shown in the lower panel, expressed relative to wild type. Consistent with previous results, FimD presence is sharply reduced in the surA mutant. FimD is restored upon complementation with full-length SurA. The N-C variant substantially restores FimD stability, and addition of domain I (but not domain II) augments this phenotype. Domains I and/or II alone provide minimal chaperone function. Cross-reacting bands are included in the figure to demonstrate overall protein loading.

doi:10.1371/journal.pone.0003359.g005
Bacterial systems supporting the maturation, assembly, and insertion of outer membrane proteins are of critical importance to membrane integrity and function, including filtering, permeability, and secretion. In recent years much has been learned about the trafficking and assembly of pores into the OM. SurA appears to key the periplasmic transit of nascent, monomeric OMP species, delivering these to the OMP assembly complex anchored by BamA, itself an OMP. Indeed, recent data demonstrate a direct biochemical interaction of SurA with BamA in vivo [16]. Putative OMP sequences targeted for binding by SurA have been identified [20,22], and the present study augments earlier findings regarding the portions of SurA critical for its chaperoning of OMPs [14,23,30]. Despite these advances, the spectrum of SurA-dependent OMPs is not precisely defined. While structural details of SurA interaction with model peptides have recently been published [30], similar demonstration of its binding to one or more in vivo OMP substrates is needed for a more complete understanding of its mechanism of action. Our ongoing studies aim to delineate the range of SurA-dependent proteins, to demonstrate direct SurA-substrate interactions, and to interrogate the structural details of the chaperone-substrate relationship.

Knowledge at a molecular level of the mechanisms of SurA function will also inform the development of small-molecule inhibitors of this important and conserved chaperone. Of primary interest, such an inhibitor might prove a valuable anti-virulence compound against Gram-negative pathogens. As a primary example, SurA provides pleiotropic support to virulence of uropathogenic E. coli. We have shown here that SurA keys type 1 pilation, a primary determinant in cystitis; but SurA-dependent proteins also support the intracellular phenotypes of UPEC [29] and unpublished data) and the local suppression of epithelial proinflammatory cytokines [25]. Beyond E. coli, SurA is conserved in other Gram-negative pathogens, such as Salmonella, Yersinia, and Shigella; and a Salmonella surA mutant was attenuated after oral inoculation in mice [31]. In the laboratory, a genetic method for incremental control of surA expression (and thus SurA function) has recently been demonstrated [16]. However, an available inhibitor would simplify this control, offering broad potential applications in the study of Gram-negative envelope biology and outer membrane biogenesis.

**Acknowledgments**

We thank S. Behrens for the SurA domain constructs, C. Cannon for helpful discussions, and S. Justice and J. Loughman for critical review of the manuscript.

**Author Contributions**

Conceived and designed the experiments: DAH. Performed the experiments: KMW. Analyzed the data: KMW DAH. Wrote the paper: KMW DAH.

**References**

1. Kim S, Malinverni JC, Sliz P, Silhavy TJ, Harrison SC, et al. (2007) Structure and function of an essential component of the outer membrane protein assembly machine. Science 317: 961-964.

2. Malinverni JC, Werner J, Kim S, Sliz JG, Kahne D, et al. (2006) YfiO stabilizes the YaeT complex and is essential for outer membrane protein assembly in Escherichia coli. Mol Microbiol 61: 151-164.

3. Wu T, Malinverni J, Ruiz N, Kim S, Silhavy TJ, et al. (2005) Identification of a multicomponent complex required for outer membrane biogenesis in Escherichia coli. Cell 121: 233-245.

4. Liu J, Walsh CT (1990) Peptidyl-prolyl cis-trans-isomerase from Escherichia coli: a periplasmic homolog of cyclophilin that is not inhibited by cyclosporin A. Proc Natl Acad Sci U S A 87: 4028-4032.

5. Horne SM, Young KD (1995) Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. Arch Microbiol 163: 357-365.

6. Lazar SW, Kolter R (1996) SurA assists the folding of outer membrane proteins in Escherichia coli. Mol Microbiol 20: 185-190.

7. Dartigalongue G, Raina S (1998) A new heat-shock gene, pdcP, encodes a peptidyl-prolyl isomerase required for folding of outer membrane proteins in Escherichia coli. EMBO J 17: 3969-3980.

8. Dougay AR, Silhavy TJ (2004) Quality control in the bacterial periplasm. Biochim Biophys Acta 1694: 121-134.

9. Shaw PE (1996) Peptidyl-prolyl isomerases: a new twist to transcription. EMBO Rep 5: 521-526.

10. Arie JP, Sassoon N, Betton JM (2001) Chaperone function of FkpA, a heat shock protein, in the periplasm of Escherichia coli. Mol Microbiol 39: 199-210.

11. Ramm K, Plückthun A (2000) The periplasmic Escherichia coli peptidylprolyl cis-trans-isomerase FlpA. Isomerase-independent chaperone activity in vivo. J Biol Chem 275: 16716-16722.

12. Rouvière PE, Gross CA (1996) A periplasmic protein with peptidyl-prolyl cis-trans isomerase activity, participates in the assembly of outer membrane pores. Genes Dev 10: 3170-3175.

13. Justice SS, Hunstad DA, Harper JR, Silhavy TJ, et al. (2003) Quality control in the bacterial periplasm. Biochemistry 42: 12051-12062.

14. Doucet E, McKay DB (2002) Crystallographic structure of SurA, a molecular chaperone that facilitates folding of outer membrane porins. Structure (Camb) 10: 1499-1498.

15. Rizzitello AE, Harper JR, Silhavy TJ, et al. (2003) The periplasmic molecular chaperone protein SurA binds a peptide motif that is characteristic of integral outer membrane proteins. J Biol Chem 276: 49316-49322.

16. Bitto E, McKay DB (2004) Binding of phage-display-selected peptides to the periplasmic chaperone protein SurA mimics binding of unfolded outer membrane proteins. FEBS Lett 568: 94-98.

17. Hemmcke G, Nohe J, Volkenr-Kengert R, Schneider-Mergener J, Behrens S (2005) The periplasmic chaperone SurA exploits two features characteristic of integral outer membrane proteins for selective substrate recognition. J Biol Chem 280: 23540-23548.

18. Hand PL, Ruddle LW, Marchant RJ, Jonas K, Klappa P (2001) Interaction of the periplasmic peptidylprolyl cis-trans isomerase SurA with model peptides. The N-terminal region of SurA is essential and sufficient for peptide binding. J Biol Chem 276: 45622-45627.

19. Malve A, Schilling JD, Hultgren SJ (2001) Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 69: 4572-4579.

20. Hunstad DA, Justice SS, Hunstad DA, Hultgren SJ (2005) Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect Immun 73: 3999-4006.

21. Martinez J, Malve MA, Schilling JD, Pinkner JS, Hultgren SJ (2000) Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19: 2803-2812.

22. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR (1978) Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 75: 4830-4834.

23. Justice SS, Lauer SR, Hultgren SJ, Hunstad DA (2006) Maturation of intracellular Escherichia coli communities requires SurA. Infect Immun 74: 4793-4800.

24. Elsinghorst EA (1994) Measurement of invasion by gentamicin resistance. J Bacteriol 176: 7680-7686.

25. Liu J, Walsh CT (1990) Peptidyl-prolyl cis-trans-isomerase required for folding of outer membrane proteins in Escherichia coli. J Bacteriol 183: 6794-6800.

26. Martinez J, Malve MA, Schilling JD, Pinkner JS, Hultgren SJ (2000) Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19: 2803-2812.

27. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR (1978) Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 75: 4830-4834.

28. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR (1978) Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc Natl Acad Sci U S A 75: 4830-4834.